American College of Cardiology

BRAUNWALD ET AL., MANAGEMENT OF PATIENTS WITH UNSTABLE ANGINA AND NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UPDATE
http://www.acc.org/clinical/guidelines/unstable/update_index.htm

ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)

This is a Guideline Update of the 2000 Unstable Angina Guidelines. To highlight the changes, deleted text is indicated by strikeout, and revised text is presented in brown. A clean version of the document, with changes fully incorporated, is available for download and print.

Figure 10. Kaplan-Meier curves showing cumulative incidence of death or MI in patients randomly assigned to platelet GP IIb/IIIa receptor antagonist (bold line) or placebo. Data are derived from the CAPTURE, PURSUIT, and PRISM-PLUS trials ⁽²⁴⁸⁾ Left, Events during the initial period of medical treatment until the moment of PCI or CABG. In the CAPTURE trial, abciximab was administered for 18 to 24 h before the PCI was performed in almost all patients as per study design; abciximab was discontinued 1 h after the intervention. In PURSUIT, a PCI was performed in 11.2% of patients during a period of medical therapy with eptifibatide that lasted 72 h and for 24 h after the intervention. In PRISM-PLUS, an intervention was performed in 30.2% of patients after a 48-h period of medical therapy with tirofiban, and the drug infusion was maintained for 12 to 24 h after an intervention. Right, Events occurring at the time of PCI and the next 48 h, with the event rates reset to 0% before the intervention. CK or CK-MB elevations exceeding 2 times the upper limit of normal were considered as infarction during medical management and exceeding 3 times the upper limit of normal for PCI-related events. Adapted from Boersma et al. ⁽²⁴⁸⁾, CAPTURE ⁽¹⁸²⁾, PURSUIT ⁽¹⁰⁾, and PRISM-PLUS ⁽²¹⁾.